Pacific Biosciences Of California | PACB - Cash And Equivalent


Pacific Biosciences Of California reported $56.27M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
General Electric Aerospace USD 10.98B 1.41B Mar/2026
Illumina USD 1.42B 368M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
Pacific Biosciences Of California USD 56.27M 223.23M Mar/2026
Quidel USD 140.4M 29.4M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Waters USD 462M 125.83M Mar/2026